Urine and Plasma Complement Ba Levels During Disease Flares in Patients With Antineutrophil Cytoplasmic Autoantibody–Associated Vasculitis

Almaani, Salem; Song, Huijuan; Suthanthira, Meshora; Toy, Christopher; Fussner, Lynn A.; Meara, Alexa; Nagaraja, Haikady; Cuthbertson, David; Khalidi, Nader A.; Koening, Curry L.; Langford, Carol A.; McAlear, Carol A.; Moreland, Larry W.; Pagnoux, Christian; Seo, Philip; Specks, Ulrich; Sreih, Antoine G.; Warrington, Kenneth J.; Monach, Paul A.; Merkel, Peter A.; Rovin, Brad; Birmingham, Daniel

doi:10.1016/j.ekir.2023.08.017

Cited by 2 publications

(1 citation statement)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study demonstrated that urinary levels of Ba were higher in vasculitis patients with renal flare, normal in non-renal flare, and remained stable in remission. In this study, the urinary Ba levels showed a better correlation with active renal vasculitis compared to plasma Ba levels, suggesting its role as a surveillance biomarker of renal vasculitis ( 101 ).…”

Section: Kidney Disease Due To Alternative Complement Pathway Activationmentioning

confidence: 58%

Urinary complement biomarkers in immune-mediated kidney diseases

Kesarwani,

Bukhari,

Kahlenberg

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

The complement system, an important part of the innate system, is known to play a central role in many immune mediated kidney diseases. All parts of the complement system including the classical, alternative, and mannose-binding lectin pathways have been implicated in complement-mediated kidney injury. Although complement components are thought to be mainly synthesized in the liver and activated in the circulation, emerging data suggest that complement is synthesized and activated inside the kidney leading to direct injury. Urinary complement biomarkers are likely a better reflection of inflammation within the kidneys as compared to traditional serum complement biomarkers which may be influenced by systemic inflammation. In addition, urinary complement biomarkers have the advantage of being non-invasive and easily accessible. With the rise of therapies targeting the complement pathways, there is a critical need to better understand the role of complement in kidney diseases and to develop reliable and non-invasive biomarkers to assess disease activity, predict treatment response and guide therapeutic interventions. In this review, we summarized the current knowledge on urinary complement biomarkers of kidney diseases due to immune complex deposition (lupus nephritis, primary membranous nephropathy, IgA nephropathy) and due to activation of the alternative pathway (C3 glomerulopathy, thrombotic microangiography, ANCA-associated vasculitis). We also address the limitations of current research and propose future directions for the discovery of urinary complement biomarkers.

show abstract

Section: Kidney Disease Due To Alternative Complement Pathway Activationmentioning

confidence: 58%